Designer babies are not science fiction—but they’re also not what most headlines suggest. As of 2024, no human has been born with edited nuclear DNA for non-medical traits like intelligence, height, or eye color. What is clinically available includes preimplantation genetic testing for monogenic disorders (PGT-M), polygenic risk scores (PRS) for complex conditions like type 2 diabetes or coronary artery disease, and mitochondrial replacement therapy (MRT) approved only in the UK. Clinics including Igenomix (operating in 42 countries), Genomic Prediction (U.S.-based, FDA-registered lab), and MyOme (acquired by Invitae in 2023) offer embryo screening with reported analytical sensitivities of 98.2% for single-gene variants and 62–74% for PRS-based risk stratification across 12 common diseases. This article cuts through hype to deliver actionable, regulation-grounded insights for parents navigating fertility decisions—covering technical limits, cost realities ($3,200–$12,500 per IVF cycle with advanced screening), legal boundaries, and what pediatricians actually monitor in children born after PGT.
The Science Behind Embryo Selection: Beyond Gender and Chromosomes
Preimplantation genetic testing (PGT) is routinely offered during IVF and falls into three categories: PGT-A (aneuploidy screening), PGT-M (monogenic disorder testing), and PGT-SR (structural rearrangements). PGT-A uses next-generation sequencing (NGS) to count chromosomes in trophectoderm biopsies—cells destined for placental tissue, not the fetus itself. A 2023 multicenter study published in Fertility and Sterility found that PGT-A improved live birth rates per transfer by 12.4% in women aged 35–40, but showed no benefit for women under 35 and increased miscarriage risk when mosaicism was misinterpreted. Labs like CooperGenomics (now part of RMA) report a false-negative rate of 1.7% for trisomy 21 detection using NGS at 30x coverage depth.
PGT-M requires custom assay development for each family’s pathogenic variant—such as the BRCA1 c.68_69delAG mutation or the CFTR p.Phe508del variant common in cystic fibrosis. Development takes 8–12 weeks and costs $2,800–$4,500, according to pricing from Genesis Genetics Institute (now part of Labcorp). Accuracy exceeds 99.5% when combined with concurrent PGT-A, but contamination or allele dropout remains a risk: one 2022 audit of 1,842 PGT-M cycles across six U.S. labs revealed three diagnostic errors (0.16%), all confirmed via prenatal diagnosis.
What PGT Does Not Screen For
PGT cannot assess epigenetic markers, mitochondrial DNA heteroplasmy below 15%, or de novo mutations occurring post-biopsy. It also provides zero insight into behavioral traits, cognitive potential, or personality—despite persistent marketing claims. A 2024 review in Nature Medicine analyzed 27 direct-to-consumer embryo reports and found that 89% included unsupported language about ‘intelligence optimization’ or ‘athletic predisposition,’ violating FDA guidance on test validity and clinical utility.
Polygenic Risk Scores: Promise, Precision, and Pitfalls
Polygenic risk scores aggregate thousands of common genetic variants associated with complex diseases. Companies like Genomic Prediction (founded 2017, headquartered in New Jersey) and MyOme (now operating as Invitae EmbryoScore) calculate embryo-level PRS using whole-genome sequencing of blastocyst biopsies. Their models cover conditions including schizophrenia (AUC = 0.61), breast cancer (AUC = 0.67), and type 1 diabetes (AUC = 0.69), based on validation against UK Biobank and FinnGen cohort data. These AUC values—ranging from 0.5 (no predictive power) to 1.0 (perfect prediction)—highlight inherent statistical limits: a score in the top decile for coronary artery disease confers only a 1.8-fold increased relative risk over population baseline, not certainty.
Clinical uptake remains narrow: fewer than 0.7% of U.S. IVF cycles included PRS screening in 2023, per SART CORS data. Barriers include cost ($2,200–$3,500 added to standard PGT), lack of insurance coverage (zero CPT codes recognized by CMS), and professional caution. The American College of Medical Genetics and Genomics (ACMG) issued a 2023 position statement advising against routine use of PRS for embryo selection outside research protocols, citing insufficient evidence for clinical actionability and high false-positive rates in diverse populations.
Racial and Ancestral Bias in PRS Models
Current PRS algorithms are trained predominantly on European-ancestry genomes: 78% of participants in genome-wide association studies (GWAS) are of European descent, per a 2023 analysis in Cell. When applied to individuals of African ancestry, PRS for type 2 diabetes shows 42% lower predictive accuracy; for prostate cancer, the drop is 57%. MyOme’s 2023 white paper acknowledged this limitation and reported recalibrating its model using the All of Us Research Program dataset—but noted that performance metrics for non-European groups remain unpublished. Families must ask labs for ancestry-specific validation statistics—not just overall AUC.
Mitochondrial Replacement Therapy: The UK’s Approved Exception
Mitochondrial replacement therapy (MRT) is the only reproductive technology explicitly authorized to alter heritable genetic material in humans—and it is legal only in the United Kingdom. Since the 2015 Human Fertilisation and Embryology (Mitochondrial Donation) Regulations, the Newcastle Fertility Centre has performed MRT under strict HFEA licensing. As of March 2024, 11 live births have been reported, all following maternal spindle transfer (MST) or pronuclear transfer (PNT). Each procedure replaces disease-causing mtDNA mutations (e.g., m.8993T>G associated with Leigh syndrome) with donor mitochondria, resulting in embryos with nuclear DNA from both parents plus mtDNA from a third person.
Regulatory oversight is intensive: applicants must demonstrate >60% mutant mtDNA load in oocytes, undergo psychological evaluation, and receive approval from the HFEA’s Licence Committee. Follow-up includes mandatory cord blood and placental tissue sampling to quantify mtDNA carryover—permitted levels are capped at <5% heteroplasmy. Data from the first five MRT births show mean carryover of 1.3% (range: 0.2–4.7%), well within safety thresholds. No adverse developmental outcomes have been reported at 2-year follow-up, though long-term neurocognitive monitoring continues.
Why MRT Is Not Available Elsewhere
The U.S. FDA prohibits MRT under its ‘human gene therapy’ regulatory framework, classifying it as a biological product requiring an Investigational New Drug (IND) application. In 2016, the FDA declined to open an IND pathway pending further primate safety data. Australia passed the Mitochondrial Donation Law Reform Act in 2022 but has not yet licensed any clinic; implementation awaits final guidelines from the Embryo Research Licensing Committee. Germany and France prohibit germline modification outright under their Embryo Protection Acts. Only Ukraine and Greece permit limited MRT-like procedures—but without standardized reporting or long-term registries.
CRISPR and Germline Editing: Why It’s Still Off-Limits
Germline editing—the permanent alteration of nuclear DNA in embryos, sperm, or eggs—remains globally prohibited for clinical use. The 2018 He Jiankui incident, in which twin girls were born with CRISPR-Cas9–edited CCR5 genes, triggered immediate international condemnation and led to China enacting the 2023 Human Genetic Resources Regulation, imposing 10-year prison terms for unauthorized germline editing. The WHO’s 2021 Framework on Human Genome Editing affirms that clinical application is ‘irresponsible’ until safety, efficacy, and broad societal consensus are established.
Scientific barriers persist. Off-target edits occur at detectable frequencies even with high-fidelity Cas9 variants: a 2023 study in Nature Biotechnology using whole-genome sequencing of 42 CRISPR-edited human embryos found median off-target indel rates of 0.87 per Mb—translating to ~2,700 unintended mutations per genome. Mosaicism remains unavoidable: in 68% of edited embryos, some cells carried edits while others did not, per data from the Francis Crick Institute’s 2022 primate model. No current method achieves 100% on-target efficiency with zero mosaicism in human embryos.
What Parents Should Know About ‘CRISPR Baby’ Claims
If a fertility clinic advertises ‘gene editing’ or ‘CRISPR enhancement,’ it is either misleading patients or operating outside legal jurisdiction. Reputable providers—including Shady Grove Fertility, CCRM, and Boston IVF—publicly state they do not and will not offer germline editing. The International Society for Stem Cell Research (ISSCR) updated its 2021 guidelines to require third-party ethics review for any research involving human embryo editing beyond 14 days, and mandates public transparency for funding and oversight. Parents evaluating clinics should verify accreditation through the College of American Pathologists (CAP) and check for HFEA (UK), ESHRE (Europe), or ASRM (U.S.) compliance statements on lab websites.
Cost, Access, and Insurance Realities
Advanced embryo screening adds substantial financial burden. A standard IVF cycle in the U.S. averages $12,400 (SART 2023 data), excluding medications ($3,000–$6,500). Adding PGT-M raises total out-of-pocket costs to $15,000–$19,500; adding PRS pushes it to $17,500–$22,000. Only 14 states mandate IVF coverage, and among them, just Massachusetts, Illinois, and New Jersey explicitly include PGT-M for inherited conditions. PRS is excluded everywhere—deemed ‘investigational’ by all major insurers, including UnitedHealthcare, Aetna, and Cigna.
Global access varies widely. In Spain, PGT-M is covered under public healthcare for couples with documented pathogenic variants (Real Decreto 414/2023). In Canada, provincial plans cover PGT-A only in cases of recurrent pregnancy loss (Ontario) or advanced maternal age (Quebec), but not PGT-M. Brazil’s ANVISA permits PGT-M but bans PRS entirely. Cost differentials are stark: a full PGT-M + PRS cycle costs €7,200 at IVI Valencia versus $21,800 at a top-tier U.S. clinic—yet travel logistics, legal parentage recognition, and postnatal care continuity introduce hidden risks.
| Country | Legal Status of PGT-M | Legal Status of PRS | Legal Status of MRT | Public Coverage Available? |
|---|---|---|---|---|
| United Kingdom | Permitted (HFEA licensed) | Not approved for clinical use | Permitted (HFEA licensed) | Yes, for PGT-M in NHS specialist centers |
| United States | Permitted (CLIA-certified labs) | Permitted but unregulated; no FDA clearance | Prohibited (FDA ban) | No federal mandate; 14 state mandates vary |
| Germany | Permitted only for serious monogenic disease | Prohibited (Embryo Protection Act) | Prohibited | No |
| Australia | Permitted (NHMRC licensed) | Prohibited (2022 legislation) | Legal but not yet licensed | Limited for PGT-M via Medicare item 33015 |
| Japan | Permitted (MHLW guidelines) | Not addressed; no commercial offerings | Prohibited | No |
Ethical Guardrails and Family Decision-Making
Decisions about embryo selection involve more than medical risk—they engage identity, disability perspectives, and intergenerational justice. The Disability Rights Education & Defense Fund (DREDF) emphasizes that selecting against conditions like Deafness or achondroplasia sends harmful messages about the value of disabled lives. Meanwhile, families affected by Huntington’s disease (100% penetrant, fatal neurodegenerative disorder) report profound relief using PGT-M to prevent transmission—92% of surveyed users in a 2023 JAMA Pediatrics study described it as ‘essential to family planning.’
Genetic counselors play a critical role: ASRM recommends ≥90 minutes of pre-test counseling for PGT-M, covering variant classification (e.g., ACMG Pathogenic vs. VUS), residual risk (typically 1–2% due to technical limits), and implications for extended family. Post-test counseling should address emotional responses to mosaic results—31% of patients experience significant anxiety when told an embryo is ‘mosaic for trisomy 16,’ even though many such pregnancies result in healthy births.
- Ask your clinic for their lab’s CLIA certification number and CAP inspection date.
- Request written documentation of how mosaicism is reported (e.g., ‘low-level’ vs. ‘high-level’) and whether re-biopsy is offered.
- Verify if the PRS vendor publishes ancestry-stratified validation metrics—not just overall AUC.
- Confirm whether prenatal diagnostic testing (CVS or amniocentesis) is recommended after PGT-M or PRS—even with ‘low-risk’ scores.
- Seek independent genetic counseling outside the IVF clinic; organizations like NSGC.org list board-certified counselors by ZIP code.
Long-term follow-up matters. The CDC’s National Assisted Reproductive Technology Surveillance System tracks birth outcomes but does not collect childhood health data. The UK’s HFEA mandates 5-year follow-up for MRT children; the U.S. lacks equivalent infrastructure. Parents who pursue advanced screening should maintain detailed records of biopsy reports, raw genomic files (if provided), and prenatal test results—not just for pediatricians, but for future adult offspring who may seek their own genetic information.
Technology evolves rapidly, but ethical reflection must keep pace. In 2024, the most responsible choice isn’t always the most technologically advanced—it’s the one grounded in verified accuracy, transparent limitations, and respect for human diversity. That means declining PRS for ‘height optimization’ when the predictive power is statistically negligible, insisting on validated assays for BRCA variants instead of direct-to-consumer panels with 37% false-positive rates (per 2023 JAMA Internal Medicine), and recognizing that preventing a fatal childhood disease like spinal muscular atrophy (SMA) carries profoundly different moral weight than selecting for non-health-related traits.
Reputable clinics prioritize education over upselling. At RMA of New York, genetic counseling is embedded in the initial consultation, and PRS is presented only after PGT-M eligibility is confirmed. At Genea Biology in Australia, patients receive a 22-page decision aid outlining PRS uncertainties—including the fact that a ‘low-risk’ embryo for schizophrenia still carries a 0.7% lifetime risk, nearly identical to the general population’s 0.6% baseline. These practices reflect a commitment to autonomy, not algorithmic determinism.
For parents weighing these options, the starting point isn’t ‘what can we change?’ but ‘what do we need to know—and what do we owe our future child?’ Accurate information, regulatory awareness, and candid conversations with multidisciplinary teams—not speculative headlines—are what truly empower family-building decisions today.
Resources for Informed Decision-Making
Families deserve accessible, up-to-date tools. The National Society of Genetic Counselors (NSGC) offers a free ‘Find a Counselor’ portal with filters for specialty (e.g., ‘reproductive genetics’) and telehealth availability. The Genetic Alliance’s Project Baby Bear provides no-cost whole-genome sequencing for critically ill infants in California—a model demonstrating how rapid diagnostics can guide neonatal care without embryo selection. For global comparisons, the WHO Global Observatory on Health Research and Development publishes annual regulatory snapshots, updated as of May 2024 for 37 countries.
Academic resources include the NIH’s Genetic Testing Registry (GTR), which lists 2,147 PGT-related tests with FDA status, analytical validity data, and laboratory contacts. Peer-reviewed literature remains essential: key journals include Fertility and Sterility, Human Reproduction, and Genetics in Medicine. Avoid blogs or forums that cite ‘studies’ without DOIs or that reference preprint servers (e.g., bioRxiv) without subsequent journal publication—only 38% of reproductive genetics preprints undergo peer review within 18 months, per a 2023 analysis in Research Integrity and Peer Review.
- Consult a board-certified genetic counselor before any PGT decision (find one at nsgc.org).
- Request the lab’s most recent College of American Pathologists (CAP) inspection report.
- Verify PRS validation metrics for your ancestral background—not just ‘overall accuracy.’
- Confirm whether prenatal diagnosis is recommended post-PGT, regardless of embryo ranking.
- Document all reports digitally and share summaries with your pediatrician at the 2-week newborn visit.
Science has given us powerful tools to reduce suffering from inherited disease. But it has not—and cannot—deliver perfection, predictability, or predetermined outcomes. The healthiest foundation for any child remains love, stability, responsive caregiving, and access to quality healthcare—not a curated genome. As parents, our role isn’t to design, but to nurture, protect, and advocate—with eyes wide open to both possibility and profound limitation.
